Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + HRS-1167
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy of bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), and HRS-1167, an oral small molecule inhibitor of poly(ADP-ribose) polymerase 1 (PARP1). Bevacizumab works by inhibiting angiogenesis in tumors, while HRS-1167 is a second-generation PARP inhibitor designed to selectively target PARP1 and disrupt DNA repair in cancer cells with homologous recombination repair defects. The combination is being investigated primarily for recurrent ovarian cancer and other advanced solid tumors. Clinical trials are ongoing to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy[1][5][8].
- Other names
- HRS-1167 + bevacizumab
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + HRS-1167.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + HRS-1167.